|
US5844092A
(en)
|
1994-03-18 |
1998-12-01 |
Genentech, Inc. |
Human TRK receptors and neurotrophic factor inhibitors
|
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
|
BR0112272A
(pt)
|
2000-06-22 |
2003-05-06 |
Genentech Inc |
Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo
|
|
MY141220A
(en)
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
|
EP1899323A2
(fr)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Dérivés de pyrazolylaminopyrimidine utiles comme inhibiteurs de tyrosine kinase
|
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
|
WO2007022999A1
(fr)
|
2005-08-25 |
2007-03-01 |
Creabilis Therapeutics S.P.A. |
Conjugues polymeres de k-252a et leurs derives
|
|
KR101145520B1
(ko)
|
2007-05-04 |
2012-05-16 |
노파르티스 아게 |
Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
|
|
ES2605230T3
(es)
|
2007-07-20 |
2017-03-13 |
Nerviano Medical Sciences S.R.L. |
Derivados de indazol sustituidos activos como inhibidores de cinasas
|
|
CA2703329A1
(fr)
|
2007-10-23 |
2009-04-30 |
Novartis Ag |
Utilisation d'anticorps trkb pour le traitement de troubles respiratoires
|
|
CA2712298C
(fr)
|
2008-01-17 |
2015-11-24 |
Irm Llc |
Anticorps anti-trkb ameliores
|
|
JP5677296B2
(ja)
|
2008-07-29 |
2015-02-25 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
グリオーマの治療のためのｃｄｋ阻害剤の使用
|
|
ES2464461T3
(es)
|
2008-09-22 |
2014-06-02 |
Array Biopharma, Inc. |
Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
|
|
TWI577680B
(zh)
|
2008-10-22 |
2017-04-11 |
亞雷生物製藥股份有限公司 |
作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
|
|
WO2010058006A1
(fr)
|
2008-11-24 |
2010-05-27 |
Nerviano Medical Sciences S.R.L. |
Inhibiteur de cdk (kinase cycline-dépendante) pour le traitement d'un mésothéliome
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
|
NZ604708A
(en)
|
2010-05-20 |
2015-05-29 |
Array Biopharma Inc |
Macrocyclic compounds as trk kinase inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
WO2012034095A1
(fr)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Composés et compositions comme inhibiteurs de trk
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
HUE030791T2
(en)
|
2011-05-13 |
2017-06-28 |
Array Biopharma Inc |
Pyrrolidinylurea, Pyrrolidinylthiocarbamind and Pyrrolidinylguanidine Compounds as Trkaquinase Inhibitors
|
|
CA2854936A1
(fr)
|
2011-11-14 |
2013-05-23 |
Tesaro, Inc. |
Modulation de certaines tyrosine kinases
|
|
KR20140105508A
(ko)
|
2011-12-12 |
2014-09-01 |
닥터 레디스 레보러터리즈 리미티드 |
트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
|
|
EP2842955B1
(fr)
|
2012-04-26 |
2016-10-05 |
ONO Pharmaceutical Co., Ltd. |
Composé inhibiteur de trk
|
|
CA2873979C
(fr)
|
2012-05-23 |
2019-11-12 |
Nerviano Medical Sciences S.R.L. |
Procede de preparation du n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazine-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
|
|
TWI585088B
(zh)
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
|
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
|
US9790210B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
AU2013344886B2
(en)
|
2012-11-13 |
2017-06-29 |
Array Biopharma Inc. |
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
|
|
DK2922844T3
(en)
|
2012-11-13 |
2018-03-05 |
Array Biopharma Inc |
N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
|
|
WO2014078322A1
(fr)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
|
|
WO2014078328A1
(fr)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
|
|
WO2014078331A1
(fr)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
|
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014129431A1
(fr)
|
2013-02-19 |
2014-08-28 |
小野薬品工業株式会社 |
COMPOSÉ INHIBANT Trk
|
|
US10407509B2
(en)
|
2013-07-30 |
2019-09-10 |
Blueprint Medicines Corporation |
NTRK2 fusions
|
|
EP3572416B1
(fr)
|
2014-01-24 |
2022-09-21 |
Turning Point Therapeutics, Inc. |
Macrocycles de diaryle en tant que modulateurs de protéines kinases
|
|
DK3102555T3
(da)
|
2014-02-05 |
2021-08-09 |
VM Oncology LLC |
Sammensætninger af forbindelser og anvendelser deraf
|
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
|
WO2015175788A1
(fr)
|
2014-05-15 |
2015-11-19 |
Array Biopharma Inc. |
1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
|
|
AU2015304438B2
(en)
|
2014-08-18 |
2019-06-20 |
Ono Pharmaceutical Co., Ltd. |
Acid-addition salt of Trk-inhibiting compound
|
|
IL290905B2
(en)
|
2014-11-16 |
2023-09-01 |
Array Biopharma Inc |
Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
|
|
US9701681B2
(en)
|
2014-12-15 |
2017-07-11 |
Cmg Pharmaceutical Co., Ltd. |
Fused ring heteroaryl compounds and their use as Trk inhibitors
|
|
RU2744852C2
(ru)
*
|
2015-10-26 |
2021-03-16 |
Локсо Онколоджи, Инк. |
Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
|
|
CA3021445A1
(fr)
*
|
2016-04-19 |
2017-10-26 |
Exelixis, Inc. |
Procede de traitement du cancer du sein negatif triple
|
|
WO2017201156A1
(fr)
*
|
2016-05-18 |
2017-11-23 |
Duke University |
Méthode de traitement du cancer colorectal métastatique kras sauvage au moyen de cabozantinib et de panitumumab
|
|
US12098428B2
(en)
|
2017-02-26 |
2024-09-24 |
Institute For Cancer Research |
Frequent EGFR and NTRK somatic mutations in colorectal cancer (CRC) with microsatellite instability (MSI)
|